Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
73.64
USD
|
-8.18%
|
|
-4.33%
|
+295.70%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
579.6
|
410.7
|
359.9
|
720.9
|
1,862
|
8,120
|
-
|
-
|
Enterprise Value (EV)
1 |
303.9
|
162.3
|
157.8
|
565.4
|
1,499
|
7,226
|
7,371
|
7,324
|
P/E ratio
|
-22.3
x
|
-10.4
x
|
-6.48
x
|
-10.4
x
|
-20.5
x
|
-65.9
x
|
-47.5
x
|
-43.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
213
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
192
x
|
EV / EBITDA
|
-9.3
x
|
-3.81
x
|
-2.83
x
|
-
|
-14.9
x
|
-51.3
x
|
-42.2
x
|
-32.8
x
|
EV / FCF
|
-9.51
x
|
-7.45
x
|
-3.32
x
|
-11.7
x
|
-20.4
x
|
-65.9
x
|
-44.3
x
|
-34.5
x
|
FCF Yield
|
-10.5%
|
-13.4%
|
-30.2%
|
-8.56%
|
-4.89%
|
-1.52%
|
-2.26%
|
-2.9%
|
Price to Book
|
2.08
x
|
1.69
x
|
1.78
x
|
4.97
x
|
5.35
x
|
9.18
x
|
11.1
x
|
-
|
Nbr of stocks (in thousands)
|
72,264
|
72,952
|
78,235
|
76,688
|
100,029
|
110,268
|
-
|
-
|
Reference price
2 |
8.020
|
5.630
|
4.600
|
9.400
|
18.61
|
73.64
|
73.64
|
73.64
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/9/22
|
2/8/23
|
2/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
38.1
|
EBITDA
1 |
-32.69
|
-42.66
|
-55.68
|
-
|
-100.8
|
-140.8
|
-174.8
|
-223.5
|
EBIT
1 |
-32.69
|
-42.66
|
-55.68
|
-70.36
|
-100.8
|
-143.6
|
-188.6
|
-196.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-514.83%
|
Earnings before Tax (EBT)
1 |
-25.78
|
-39.5
|
-54.99
|
-68.87
|
-85.9
|
-120.4
|
-170.6
|
-184.4
|
Net income
1 |
-25.78
|
-39.5
|
-54.99
|
-68.87
|
-85.9
|
-119.3
|
-171.5
|
-192.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-505.25%
|
EPS
2 |
-0.3600
|
-0.5400
|
-0.7100
|
-0.9000
|
-0.9100
|
-1.118
|
-1.549
|
-1.698
|
Free Cash Flow
1 |
-31.96
|
-21.78
|
-47.59
|
-48.4
|
-73.38
|
-109.7
|
-166.2
|
-212.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-557.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/9/22
|
2/8/23
|
2/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-12.51
|
-16.24
|
-17.63
|
-16.2
|
-
|
-20.54
|
-23.74
|
-27.26
|
-29.28
|
-34.07
|
-33.66
|
-35.55
|
-37.48
|
-
|
-
|
EBIT
1 |
-12.51
|
-16.24
|
-17.63
|
-16.2
|
-20.28
|
-20.54
|
-23.74
|
-27.26
|
-29.28
|
-34.07
|
-35.11
|
-36.56
|
-37.85
|
-48.17
|
-52.68
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.36
|
-16.1
|
-17.43
|
-15.77
|
-19.56
|
-19.53
|
-19.22
|
-22.53
|
-24.6
|
-27.36
|
-29.18
|
-30.83
|
-32.28
|
-38.77
|
-43.54
|
Net income
1 |
-12.36
|
-16.1
|
-17.43
|
-15.77
|
-19.56
|
-19.53
|
-19.22
|
-22.53
|
-24.6
|
-27.36
|
-28.77
|
-30.47
|
-31.9
|
-38.77
|
-43.54
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1600
|
-0.2100
|
-0.2300
|
-0.2100
|
-0.2600
|
-0.2500
|
-0.1900
|
-0.2300
|
-0.2500
|
-0.2600
|
-0.2691
|
-0.2827
|
-0.2964
|
-0.3133
|
-0.3400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/9/22
|
4/27/22
|
7/27/22
|
10/26/22
|
2/8/23
|
4/26/23
|
7/26/23
|
10/25/23
|
2/7/24
|
4/24/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
276
|
248
|
202
|
155
|
362
|
895
|
749
|
796
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-32
|
-21.8
|
-47.6
|
-48.4
|
-73.4
|
-110
|
-166
|
-212
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.850
|
3.340
|
2.580
|
1.890
|
3.480
|
8.020
|
6.650
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
478
|
467
|
1.5
|
1.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.94%
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/9/22
|
2/8/23
|
2/7/24
|
-
|
-
|
-
|
Last Close Price
73.64
USD Average target price
108.4
USD Spread / Average Target +47.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +295.70% | 8.12B | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|